| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.31B | 8.83B | 7.62B | 6.66B | 4.80B | 3.86B |
| Gross Profit | 4.12B | 1.87B | 4.10B | 3.81B | 2.80B | 2.10B |
| EBITDA | 1.74B | 1.63B | 1.44B | 1.18B | 900.18M | 683.81M |
| Net Income | 1.16B | 1.09B | 961.74M | 819.77M | 632.62M | 454.44M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.93B | 7.86B | 5.68B | 4.62B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 1.97B | 1.97B | 2.07B | 1.53B | 1.05B | 1.00B |
| Total Debt | 0.00 | 754.52M | 263.46M | 135.27M | 206.79M | 350.55M |
| Total Liabilities | -6.19B | 3.74B | 2.81B | 1.64B | 1.43B | 1.06B |
| Stockholders Equity | 6.19B | 6.19B | 5.05B | 4.05B | 3.18B | 2.59B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.01B | 1.15B | 763.31M | 505.42M | 627.11M |
| Operating Cash Flow | 0.00 | 1.11B | 1.17B | 841.04M | 701.17M | 697.78M |
| Investing Cash Flow | 0.00 | -1.13B | -637.68M | -593.61M | -627.03M | -114.52M |
| Financing Cash Flow | 0.00 | 276.46M | 10.54M | -107.37M | -235.63M | -112.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹26.20B | 21.76 | ― | 0.42% | 21.17% | 27.66% | |
72 Outperform | ₹27.08B | 16.17 | ― | 1.36% | 6.64% | 4.63% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | ₹21.34B | 39.45 | ― | ― | 155.87% | ― | |
56 Neutral | ₹14.07B | 43.32 | ― | 1.04% | 12.25% | -28.69% | |
54 Neutral | ₹16.08B | 72.13 | ― | 0.53% | 11.73% | -64.05% | |
52 Neutral | ₹36.23B | 517.57 | ― | 0.25% | 10.29% | ― |
Saksoft Limited has announced a virtual investor and analyst meeting scheduled for September 25, 2025, hosted by Valorem Advisors. The company plans to reiterate information from its previous earnings call for the quarter ended June 30, 2025, ensuring no unpublished price sensitive information will be shared during the meeting.
Saksoft Limited announced the approval of its unaudited financial results for the quarter ending June 30, 2025, with no adverse remarks from auditors. Additionally, the company approved a Scheme of Amalgamation with Augmento Labs Private Limited, subject to necessary approvals, which may enhance its market position and operational capabilities.